Skip to main
BLFS
BLFS logo

BioLife Solutions (BLFS) Stock Forecast & Price Target

BioLife Solutions (BLFS) Analyst Ratings

Based on 13 analyst ratings
Strong Buy
Strong Buy 62%
Buy 38%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BioLife Solutions Inc. has demonstrated consistent financial growth, highlighted by a 12% year-over-year increase in Cell Processing revenue, reaching $73.5 million in 2024, alongside a sequential revenue growth of 7% to $20.3 million in 4Q24. The company has also raised its FY24 guidance for the Cell Processing platform, projecting revenue between $72 million and $73 million, and is anticipating a further 15% year-over-year increase in FY25 revenue, with projections of $82 million to $85 million. Furthermore, the strong demand for its biopreservation media, coupled with recent divestitures of non-core products aimed at enhancing margins, supports management's expectations of significant revenue and gross margin growth moving forward.

Bears say

BioLife Solutions Inc faces significant risks that could negatively impact its financial performance, including lower-than-expected growth of its products and services as well as challenges in acquiring new customers. The company reported a net loss of $11.4 million, equating to a loss of $0.25 per share, indicating ongoing financial difficulties. Additionally, there are concerns regarding potential disruptions to its manufacturing and supply chain, which could further exacerbate these financial challenges.

BioLife Solutions (BLFS) has been analyzed by 13 analysts, with a consensus rating of Strong Buy. 62% of analysts recommend a Strong Buy, 38% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BioLife Solutions and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BioLife Solutions (BLFS) Forecast

Analysts have given BioLife Solutions (BLFS) a Strong Buy based on their latest research and market trends.

According to 13 analysts, BioLife Solutions (BLFS) has a Strong Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.54, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.54, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BioLife Solutions (BLFS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.